Delveinsight Business Research LLP

DelveInsight’s ‘Hematopoietic Stem Cell Transplantation (HSCT) – Market Insights, Epidemiology, and Market Forecast–2032’ report delivers an in-depth understanding of HSCT historical and forecasted epidemiology as well as the HSCT market trends in the United States, EU-5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

 The HSCT market report provides current treatment practices, emerging drugs, and market share of individual therapies, current and forecasted 7MM HSCT market size. The report also covers HSCT procedure, SWOT analysis, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Some of the key facts of the Hematopoietic Stem Cell Transplantation Market Report:

• In terms of indications for HSCT, multiple myeloma/plasma cell disorders bags the largest pool among all the considered indications in the 7MM except for Japan.

• In 2021, the cases of multiple myeloma/plasma cell disorders; acute myeloid leukemia; non-Hodgkin lymphoma; acute lymphocytic leukemia; myelodysplastic syndromes/myeloproliferative neoplasms; and Hodgkin lymphoma in the EU-5 were ~9,000; ~3,900; 4,000; 1,900; 2,100; and 1,400 cases respectively. The cases for other malignant and non-malignant diseases in the EU-5 were ~1,600 and ~1,900 respectively in 2021.

• In terms of type-specific cases of HSCT, the percentage of autologous HSCT cases is more in comparison to allogeneic HSCT across the 7MM except for Japan.

• Total allogeneic HSCT cases in the EU-5 accounted for ~10,000 cases, whereas, autologous cases accounted for ~16,000 cases in the year 2021.

• In 2021, the type-specific cases of HSCT in Japan were ~3,800 and ~2,100 for allogeneic HSCT and autologous HSCT respectively. 

Key Benefits of the Report:

• The report covers the descriptive overview of Hematopoietic Stem Cell Transplantation, explaining its causes, signs, and symptoms, pathophysiology, diagnosis, and currently available therapies

• Comprehensive insight has been provided into the Hematopoietic Stem Cell Transplantation epidemiology and treatment in the 7MM

• Additionally, an all-inclusive account of both the current and emerging therapies for Hematopoietic Stem Cell Transplantation is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape

• A detailed review of the Hematopoietic Stem Cell Transplantation market; historical and forecasted is included in the report, covering drug outreach in the 7MM

• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Hematopoietic Stem Cell Transplantation market.

 Got queries? Click here to know more about the  Hematopoietic Stem Cell Transplantation Market  Landscape 

 Hematopoietic Stem Cell Transplantation Overview

 Hematopoietic stem cell transplantation (HSCT) administers healthy hematopoietic stem cells (HSC) to patients with defective or depleted bone marrow. This improves bone marrow function and, depending on the disease being treated, leads to either the destruction of malignant tumor cells or the generation of functional cells that can replace the dysfunctional ones, as in the case of immune-deficiency syndromes, hemoglobinopathies, and other diseases.

HSCs are immature blood cells found in the peripheral blood and the bone marrow. These are also called blood stem cells. These are produced in the bone marrow and can develop into any type of blood cell required by the body. Stem cells divide and mature, replacing older and worn-out blood cells. Many major health issues can emerge if the stem cells cannot produce enough new blood cells. Infections, anemia, and bleeding are examples of such issues. Healthy stem cells are required for survival. Stem cell transplantation (SCT) may be the best therapy option when cancer or cancer therapies eliminate the stem cells.

 Hematopoietic Stem Cell Transplantation Epidemiology Insights: 

• Hematopoietic progenitor cells (HPCs) or hematopoietic stem cells (HSCs) are blood and bone marrow cells. HPCs are capable of forming mature blood cells, such as red blood cells (the cells that carry oxygen), platelets (the cells that help stop bleeding), and white blood cells (the cells that fight infections).HPCs are used to treat malignant (e.g., leukemia, lymphoma) and non-malignant (e.g., sickle cell disease) diseases to replace or rebuild a patient’s hematopoietic system. This type of treatment is called a bone marrow or stem cell transplant. HPCs have also been used to treat autoimmune diseases, genetic diseases, and other indications.

• The total cases of HSCT in the 7MM were ~ 56,000 in 2021, which is expected to increase during the forecast period.

• Among 7MM, the United States had the highest number of cases (~ 24,000 cases) in 2021, for HSCT in the 7MM. The US accounted for ~43% of the total HSCT cases in 7MM

• In the EU-5, Germany had the highest number of cases (~7,100 cases), followed by France with ~5,200 cases, while Spain had the least number of cases (~3,400  cases) in 2021.

• In 2021, Japan accounted for approximately 10% of the total HSCT cases in the 7MM. Japan had ~5,900 cases of HSCT in 2021.

 Hematopoietic Stem Cell Transplantation Epidemiological Segmentation 

• Hematopoietic Stem Cell Transplantation market cases 

•  Hematopoietic Stem Cell Transplantation market cases by indication

• Hematopoietic Stem Cell Transplantation market type-specific cases 

Hematopoietic Stem Cell Transplantation Market Outlook

Hematopoietic stem cell transplantation using hematopoietic progenitor cells from the patient (autologous HSCT) or a donor (allogeneic HSCT) is a potentially curative therapy for many life-threatening cancers and non-malignant disorders. Transplantation of hematopoietic stem cells (HSCT) has become the standard of care for many patients with defined congenital or acquired disorders of the hematopoietic system or with chemo- radio- or immuno- sensitive malignancies. Over the last two decades, HSCT has seen rapid expansion and a constant evolution in technology use. Multiple myeloma and non-Hodgkin’s lymphoma remain the most common indications for high-dose chemotherapy and autologous peripheral blood stem cell rescue. Hematopoietic stem cell transplantation (HSCT) can be curative for hematologic malignancies. As a result of receiving preparative treatments for HSCT (“conditioning”) involving high-dose chemotherapy with/without total body irradiation (TBI), patients become profoundly immunocompromised and prone to opportunistic infections while awaiting donor immune reconstitution. These infectious risks and other complications including graft rejection, graft-versus-host disease (GVHD), and disease relapse, have been the main obstacles to HSCT success. 

 Learn more by requesting for sample @ Hematopoietic Stem Cell Transplantation Market  Landscape

Table of Contents

1.  Key Insights 

2.  Report Introduction 

3.  Executive Summary of  Hematopoietic Stem Cell Transplantation Market 

4.  Disease Background and Overview

5.  Epidemiology and patient population

6.  The United States 

7.  EU 5

8.  Hematopoietic Stem Cell Transplantation Market  Market  Emerging Therapies

9.  Hematopoietic Stem Cell Transplantation Market  Market Cancer Market Outlook

10.  Market Access and Reimbursement of Therapies

11.  Appendix

12.  Hematopoietic Stem Cell Transplantation Market  Market   Report Methodology

13.  DelveInsight Capabilities

14.  Disclaimer

15. About DelveInsight

Click here to read more about Hematopoietic Stem Cell Transplantation Market Landscape

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com